Ute to tumour improvement not simply through SASP but also exosomes for the duration of aging course of action. Summary/Conclusion: Here we show a novel function of exosomes PKCθ list secreted from senescent cells on chromosomal instability. These data recommend that senescenceassociated exosome secretion may contribute to agerelated improve of cancer incidence. Funding: PRESTO, JST.OF15.Orthotopic neuroblastoma tumour model creating GFP-labelled extracellular vesicles (EV) reveals particular capture of GPF EV by monocytes/macrophages and mesenchymal cells in liver and bone marrow Yves A. DeClercka, Laurence Blavierb and Rie Nakataca University of Southern California, Los Angeles, CA, USA; bChildren’s Hospital Los Angeles, LosAngeles, CA, USA; cChildren’s Hospital Los Angeles, Los Angeles, CA, USAResults: Preliminary experiments with PKH67-stained NB-derived EV injected i.v. showed that just after 24 h 0.91 of CD 45+cells within the BM, six.70.3 of CD105 + cells inside the bone, and 0.two.two of CD45+ in the liver and lung contained green vesicles. In mice orthotopically implanted with NB cells making GFP-labelled EV, we observed an growing volume of GD2- /GFP+ cells in the BM (0.2) in between week 2 and six. The expression of CD45, CD11b, and CD105 in these GD2- cells suggests their myeloid, monocytic, and mesenchymal origin. In the liver, a similar capture by CD45+ and CD11b+ was observed (up to 0.2). We also observed an rising volume of GD2- /GFP+ cells that had been unfavorable for CD45, CD11b, and CD105 at week 6. No GFP+ cells were detected within the lung, spleen and kidney. Summary/Conclusion: Tumour-derived exosomes are particularly captured by a tiny percentage (within the limits of FACS detection) of myeloid and stromal cells inside the BM plus the liver inside the early stages of tumour development just before NB cells dwelling to these organs. The data which employed an orthotopic model rather i.v. injection, help the notion that exosomes contribute to the pre-metastatic niche. Funding: RO1 CA 207983 in the National Institutes of Health, USA.OF15.ExoBow a transgenic tactic to study CD63+extracellular vesicles in vivo B bara Adema, Nuno p70S6K site Bastosa, Carolina Ruivoa, Maxwell Goodrichb, Zhang Xiaojingc, Barbara Seidlerd, David W Goodriche, Jose L Costaf, JosMachadof, Dieter Saurg, Dawen Caih and S ia Melof i3S Instituto de Investiga o e Inova o em Sa e, Porto University, Portugal; IPATIMUP Instituto de Patologia e Imunologia Molecular da Universidade do Porto; ICBAS Instituto de Ci cias Biom icas Abel Salazar da Universidade do Porto, Porto, Portugal; bDepartment of Pharmacology Therapeutics, Roswell Park Comprehensive Cancer Center, New york, NY, USA; 34Department of Pharmacology Therapeutics, Roswell Park Extensive Cancer Center, New York, NY, USA; d German Cancer Study Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, heidelberg, Germany; eDepartment of Pharmacology Therapeutics, Roswell Park Complete Cancer Center, New York, NY, USA; fi3S Instituto de Investiga o e Inova o em Sa e, Porto University, Portugal; IPATIMUP Instituto de Patologia e Imunologia Molecular da Universidade do Porto; FMUP Faculdade de Medicina da Universidade do Porto, Porto, Portugal; gGerman Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany, Heidelberg, Germany; hUniversity of Michigan Health-related School, Ann Arbor, MI, USA.aIntroduction: EV released by tumours reaches target cells at distant sites. The study of their capture in vivo has been restricted.